Cargando…
Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease
BACKGROUND: Neuroinflammation has gained increasing attention as a potential contributing factor in Alzheimer’s disease (AD) pathology. A clinical cerebrospinal fluid biomarker capable of monitoring this process during the course of the disease has yet to emerge, chiefly owing to contradictory resea...
Autores principales: | Brosseron, Frederic, Traschütz, Andreas, Widmann, Catherine N., Kummer, Markus P., Tacik, Pawel, Santarelli, Francesco, Jessen, Frank, Heneka, Michael T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828084/ https://www.ncbi.nlm.nih.gov/pubmed/29482610 http://dx.doi.org/10.1186/s13195-018-0353-3 |
Ejemplares similares
-
Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview
por: Brosseron, Frederic, et al.
Publicado: (2014) -
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers
por: Suárez‐Calvet, Marc, et al.
Publicado: (2016) -
Longitudinal Neurocognitive and Pulmonological Profile of Long COVID-19: Protocol for the COVIMMUNE-Clin Study
por: Widmann, Catherine N, et al.
Publicado: (2021) -
PPARs in Alzheimer's Disease
por: Kummer, Markus P., et al.
Publicado: (2008) -
Proteome profiling of s-nitrosylated synaptosomal proteins by isobaric mass tags
por: Wijasa, Teodora Stella, et al.
Publicado: (2017)